Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS
UK-based specialist pharmaceutical firm Mallinckrodt has begun patient enrolment in the Phase IV OPTIONS clinical trial of HP Acthar gel to manage exacerbations in relapsing and remitting multiple sclerosis (RRMS) patients.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news